FranceResearch and clinical trials
Enzyme therapy every 3-4 weeks may be enough for patients with stable Gaucher disease
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
In France, the interval of enzyme therapy was studied in patients with stable type 1 Gaucher disease. A total of 63 patients treated every 3-4 weeks instead of every two weeks were compared with 215 patients. The patients were followed for an average of 6 years. Bone problems, anemia and low platelet counts were similarly frequent in the two groups. Those treated less often received, on average, 55 fewer infusions per patient.
What does it mean for patients and families?
This is a registry study, not a randomized trial. Do not change your treatment interval on your own; talk to your doctor.
Source
Scientific paper: Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non‐inferiority sequential trial emulation. Journal of Internal Medicine, 2026. DOI: 10.1111/joim.70079 · PubMed 41761869
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Gaucher disease
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.